---
schema_version: "secwatch.filing_event.v1"
accession: "0002007919-25-000083"
form_type: "8-K"
ticker: "INBX"
cik: "0002007919"
company_name: "Inhibrx Biosciences, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T14:03:20.463419+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Inhibrx reports Q2 net loss of $28.7M; cash $186.6M; key trial data expected Q4 2025

## Summary
- Net loss of $28.7M ($1.85/share) vs net income of $1.9B in Q2 2024 due to $2B gain from 101 transaction.
- Revenue $1.3M (up from $0.1M); R&D $22.3M (-67% YoY); G&A $6.4M (-93% YoY).
- Cash and equivalents $186.6M at June 30, down from $216.5M at March 31.
- Ozekibart (INBRX-109) Phase 2 chondrosarcoma trial fully enrolled; results expected by late Oct 2025.
- Initial Phase 2 data for INBRX-106 in head/neck cancer + pembrolizumab expected in Q4 2025.

## SEC filing metadata
- accession: 0002007919-25-000083
- form_type: 8-K
- ticker: INBX
- cik: 0002007919
- company_name: Inhibrx Biosciences, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2007919/000200791925000083/0002007919-25-000083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2007919/000200791925000083/inhibrx-20250813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002007919-25-000083
- JSON: https://secwatch.observer/filing/0002007919-25-000083.json
- Plain text: https://secwatch.observer/filing/0002007919-25-000083.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.